JP2022516389A5 - - Google Patents

Info

Publication number
JP2022516389A5
JP2022516389A5 JP2020566903A JP2020566903A JP2022516389A5 JP 2022516389 A5 JP2022516389 A5 JP 2022516389A5 JP 2020566903 A JP2020566903 A JP 2020566903A JP 2020566903 A JP2020566903 A JP 2020566903A JP 2022516389 A5 JP2022516389 A5 JP 2022516389A5
Authority
JP
Japan
Prior art keywords
inkt
chain variable
cells
car
scfv
Prior art date
Application number
JP2020566903A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022516389A (ja
JPWO2019232477A5 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/035052 external-priority patent/WO2019232477A2/en
Publication of JP2022516389A publication Critical patent/JP2022516389A/ja
Publication of JPWO2019232477A5 publication Critical patent/JPWO2019232477A5/ja
Publication of JP2022516389A5 publication Critical patent/JP2022516389A5/ja
Pending legal-status Critical Current

Links

JP2020566903A 2018-05-31 2019-05-31 血液悪性腫瘍を治療するためのゲノム編集インバリアントナチュラルキラーＴ（ｉＮＫＴ）細胞 Pending JP2022516389A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862678883P 2018-05-31 2018-05-31
US62/678,883 2018-05-31
PCT/US2019/035052 WO2019232477A2 (en) 2018-05-31 2019-05-31 Genome-edited invariant natural killer t (inkt) cells for the treatment of hematologic malignancies

Publications (3)

Publication Number Publication Date
JP2022516389A JP2022516389A (ja) 2022-02-28
JPWO2019232477A5 JPWO2019232477A5 (https=) 2022-06-07
JP2022516389A5 true JP2022516389A5 (https=) 2022-06-07

Family

ID=68697140

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020566903A Pending JP2022516389A (ja) 2018-05-31 2019-05-31 血液悪性腫瘍を治療するためのゲノム編集インバリアントナチュラルキラーＴ（ｉＮＫＴ）細胞

Country Status (5)

Country Link
US (2) US20200040056A1 (https=)
EP (1) EP3801568A4 (https=)
JP (1) JP2022516389A (https=)
CN (1) CN112584844A (https=)
WO (1) WO2019232477A2 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ750256A (en) 2016-08-03 2026-02-27 Dipersio John F Gene editing of car-t cells for the treatment of t cell malignancies with chimeric antigen receptors
SG11202104524YA (en) 2018-11-01 2021-05-28 Gracell Biotechnologies Shanghai Co Ltd Compositions and methods for t cell engineering
CN109735558B (zh) * 2018-12-12 2022-04-15 中南大学 一种重组car19-il24基因、慢病毒载体、car19-il24-t细胞及应用
JP2022526340A (ja) * 2019-03-25 2022-05-24 マックス－デルブリュック－ツェントルム フューア モレキュラーレ メディツィン イン デア ヘルムホルツ－ゲマインシャフト Ｅｂａｇ９を阻害することによる細胞溶解性ｔ細胞の活性の増強
IL322315A (en) 2019-05-14 2025-09-01 Provention Bio Inc Methods and preparations for preventing type 1 diabetes
US20230113157A1 (en) * 2020-05-06 2023-04-13 Gracell Biotechnologies (Shanghai) Co., Ltd. Compositions and methods for t cell engineering
AU2021287998B2 (en) 2020-06-11 2026-03-12 Benaroya Research Institute At Virginia Mason Methods and compositions for preventing type 1 diabetes
KR20230093329A (ko) * 2020-10-28 2023-06-27 베이롤 칼리지 오브 메드신 암의 치료를 위한 면역조절 치료제로서 면역 세포에서 src-3의 표적화
CN112225822B (zh) * 2020-12-14 2021-03-23 北京基因启明生物科技有限公司 高扩增、存续能力和杀瘤作用的CAR-iNKT及应用
EP4039808A1 (en) * 2021-02-08 2022-08-10 Ospedale San Raffaele S.r.l. Guide rnas and uses thereof
CN112961854B (zh) * 2021-02-20 2022-03-29 中国人民解放军总医院第五医学中心 一种靶向IL-16基因的sgRNA、质粒组及基因敲除方法和应用
CN112980800A (zh) * 2021-03-08 2021-06-18 河北森朗生物科技有限公司 Car-t细胞、其构建方法及其应用
CN113061624B (zh) * 2021-03-09 2023-08-18 矫士平 一种敲除Tim-3基因以延长T细胞体内生存的方法
US12565529B2 (en) 2021-05-24 2026-03-03 Provention Bio, Inc. Methods for treating type 1 diabetes
CN115989244A (zh) * 2021-08-06 2023-04-18 上海驯鹿生物技术有限公司 Cd5和cd7双靶点的全人源嵌合抗原受体(car)及其应用
US20250170240A1 (en) * 2022-02-23 2025-05-29 Tinkeso Therapeutics, Inc. Modified invariant natural killer t cells expressing a chimeric antigen receptor and uses thereof
CN114644716A (zh) * 2022-04-07 2022-06-21 苏州大学 一种抗bxmas1嵌合抗原受体及其修饰的免疫细胞及应用
CA3264498A1 (en) * 2022-08-23 2024-02-29 Imperial College Innovations Limited CHIMERIC ANTIGENIC RECEPTOR (CAR) WITH A VARIABLE REGION OF TCR BETA CHAIN
CN119529098B (zh) * 2025-01-22 2025-05-30 北京可瑞生物科技有限公司 对mage-a1具有特异性的结合分子和抗cd3的融合蛋白

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2575824A4 (en) * 2010-05-24 2014-02-19 Childrens Medical Center METHOD FOR THE TREATMENT AND PREVENTION OF INFLAMMATORY DISEASES
US20170029777A1 (en) * 2014-01-27 2017-02-02 St. Jude Children's Research Hospital, Inc. Methods of expanding ex vivo natural killer t (nkt) cells and therapeutic uses thereof
JP7086375B2 (ja) * 2015-04-23 2022-06-20 ベイラー カレッジ オブ メディスン 生体内での存続性及び治療活性及びその増殖のためのｎｋｔ細胞サブセット
EP3708587B1 (en) * 2015-11-27 2024-05-22 Cartherics Pty. Ltd. Genetically modified cells and uses thereof
CA3010236A1 (en) * 2016-01-20 2017-07-27 Fate Therapeutics, Inc. Compositions and methods for immune cell modulation in adoptive immunotherapies
WO2018106595A1 (en) * 2016-12-05 2018-06-14 Fate Therapeutics, Inc. Compositions and methods for immune cell modulation in adoptive immunotherapies
WO2018195339A1 (en) * 2017-04-19 2018-10-25 Board Of Regents, The University Of Texas System Immune cells expressing engineered antigen receptors
CN107384949B (zh) * 2017-06-27 2019-01-15 闾民 表达GPC3嵌合抗原受体的iNKT细胞及制备、应用
JP2021525530A (ja) * 2018-06-01 2021-09-27 ワシントン・ユニバーシティＷａｓｈｉｎｇｔｏｎ Ｕｎｉｖｅｒｓｉｔｙ キメラ抗原受容体細胞治療薬を用いたサイトカイン放出症候群の抑制
WO2020232427A2 (en) * 2019-05-16 2020-11-19 Arch Oncology, Inc. Therapeutic compositions and methods for treating cancer in combination with analogs of interleukin proteins

Similar Documents

Publication Publication Date Title
JP2022516389A5 (https=)
JP7514746B2 (ja) 細胞
EP3586852B1 (en) Modified cell expansion and uses thereof
Zhang et al. Engineering car-t cells
Cartellieri et al. Switching CAR T cells on and off: a novel modular platform for retargeting of T cells to AML blasts
JP7179030B2 (ja) Ｒｏｒ１ ｃａｒ ｔ細胞
Chmielewski et al. T cell activation by antibody-like immunoreceptors: increase in affinity of the single-chain fragment domain above threshold does not increase T cell activation against antigen-positive target cells but decreases selectivity
JPWO2019232477A5 (https=)
JP2024174023A (ja) キメラ抗原受容体
JPWO2019232444A5 (https=)
KR20200015713A (ko) 항-trbc1 항원 결합 도메인
JP2015527070A5 (https=)
CN112638947A (zh) 用于治疗实体瘤的嵌合抗原受体细胞
CN107406517A (zh) 包含cd19结合域的嵌合抗原受体(car)
KR102316091B1 (ko) Bcma를 표적으로 하는 키메라 항원 수용체 및 이의 용도
Qian et al. The novel anti-CD19 chimeric antigen receptors with humanized scFv (single-chain variable fragment) trigger leukemia cell killing
Maruta et al. Direct comparison of target-reactivity and cross-reactivity induced by CAR-and BiTE-redirected T cells for the development of antibody-based T-cell therapy
Hombach et al. T cells engrafted with a recombinant anti-CD30 receptor target autologous CD30+ cutaneous lymphoma cells
US20230151094A1 (en) Chimeric antigen receptors targeting cd33
Märkl et al. Mutation-specific CAR T cells as precision therapy for IGLV3-21R110 expressing high-risk chronic lymphocytic leukemia
JP2025534161A (ja) 線維芽細胞活性化タンパク質（ｆａｐ）ｃａｒインバリアントナチュラルキラーｔ細胞及びその使用
EP3912992A1 (en) Car library and production method for scfv
Shirasu et al. Molecular Characterization of a Fully Human Chimeric T‐Cell Antigen Receptor for Tumor‐Associated Antigen EpCAM
Blanco et al. Autocrine costimulation: Tumor-specific CD28-mediated costimulation of T cells by in situ production of a bifunctional B7–anti-CEA diabody fusion protein
EP4606823A1 (en) Synthetic t cell receptor antigen receptor specifically binding to lilrb4 and use thereof